Bora Pharmaceuticals Co (TPE:6472) Beginning Cash Position: NT$5,077 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:6472 Bora Pharmaceuticals Co Ltd TPE:6472
82 GF Score
Price NT$382.50
GF Value NT$731.88
Valuation Significantly Undervalued
! 6 Warning Signs
View Full Analysis

What is Bora Pharmaceuticals Co Beginning Cash Position?

Bora Pharmaceuticals Co TPE:6472 -0.39% 82 Beginning Cash Position is NT$5,077 Mil as of Mar. 2026. GuruFocus rates TPE:6472 with a GF Score™ of 82/100 and a GF Value™ of NT$731.88 (Significantly Undervalued). The stock has 6 warning signs investors should review.

Bora Pharmaceuticals Co's Beginning Cash Position for the quarter that ended in Mar. 2026 was NT$5,077 Mil.

Bora Pharmaceuticals Co's quarterly Beginning Cash Position increased from Sep. 2025 (NT$4,310 Mil) to Dec. 2025 (NT$4,409 Mil) and increased from Dec. 2025 (NT$4,409 Mil) to Mar. 2026 (NT$5,077 Mil).

Bora Pharmaceuticals Co's annual Beginning Cash Position declined from Dec. 2023 (NT$3,281 Mil) to Dec. 2024 (NT$3,053 Mil) but then increased from Dec. 2024 (NT$3,053 Mil) to Dec. 2025 (NT$5,829 Mil).


Bora Pharmaceuticals Co Beginning Cash Position Related Terms


Bora Pharmaceuticals Co Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Bora Pharmaceuticals Co's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bora Pharmaceuticals Co Beginning Cash Position Chart

Bora Pharmaceuticals Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 669.99 910.75 3,281.32 3,053.29 5,829.20

Bora Pharmaceuticals Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,829.20 5,125.64 4,309.66 4,409.05 5,076.89
TPE:6472
82GF Score
Bora Pharmaceuticals Co Ltd TPE:6472
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bora Pharmaceuticals Co Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of NT$5,077 Mil mean?
Bora Pharmaceuticals Co (TPE:6472) has a Beginning Cash Position of NT$5,077 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Bora Pharmaceuticals Co and its competitors.
Is Bora Pharmaceuticals Co's Beginning Cash Position too high?
Bora Pharmaceuticals Co's current Beginning Cash Position is NT$5,077 Mil. Overall, Bora Pharmaceuticals Co has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bora Pharmaceuticals Co's Beginning Cash Position compare to ZTS?
Bora Pharmaceuticals Co's Beginning Cash Position of NT$5,077 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Drug Manufacturers company?
A good Beginning Cash Position depends on the Drug Manufacturers industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Bora Pharmaceuticals Co and its competitors. Bora Pharmaceuticals Co's current Beginning Cash Position is NT$5,077 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bora Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Bora Pharmaceuticals Co (TPE:6472) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$731.88, compared to a current price of NT$382.50 — trading 47.7% below its estimated fair value. The current Beginning Cash Position is NT$5,077 Mil. Bora Pharmaceuticals Co's overall GF Score™ is 82/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Bora Pharmaceuticals Co (TPE:6472), the current Beginning Cash Position is NT$5,077 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bora Pharmaceuticals Co (TPE:6472) Overvalued in 2026?

Based on GuruFocus' analysis, Bora Pharmaceuticals Co stock appears to be undervalued. The current stock price of NT$382.50 is trading 47.7% below its estimated GF Value™ of NT$731.88. GuruFocus considers Bora Pharmaceuticals Co to be Significantly Undervalued.

Key valuation signals for TPE:6472:

  • Beginning Cash Position: NT$5,077 Mil
  • GF Value™: NT$731.88 vs. price of NT$382.50 (47.7% below fair value)
  • GF Score™: 82/100 with 6 warning signs

No single metric tells the full story. See the TPE:6472 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bora Pharmaceuticals Co Business Description

Other Exchanges BORAY:USA
Address No. 2, Aly. 36, Lane 26, Ruiguang Road, 6th Floor, Neihu District, Taipei, TWN, 114
Bora Pharmaceuticals Co Ltd is a pharmaceutical company based in Taiwan. It covers the pharmaceutical supply chain from research and development to sales and distribution. The main activities of the Company focus on manufacturing and selling generic, brand, and over-the-counter (OTC) drugs, contract development and manufacturing (CDMO), and developing and selling consumer healthcare products. The Group operates in three reportable segments; Sales segment: sale of pharmaceuticals, generics, and healthcare products. CDMO segment: contract development and manufacturing organization of pharmaceuticals. Other segment: Others. Geographically, the company operates in the USA which derives key revenue, Europe, Taiwan, and other regions.
82GF Score

Get the complete analysis for TPE:6472

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$382.50
Price
NT$731.88
GF Value